The company had posted a net profit of Rs 130 crore in the same period of the previous fiscal.
Total income of the company during the period under review stood at Rs 1705.5 million compared with Rs 1794.6 million in the same period of the last fiscal, Novartis India said in a BSE filing.
Also Read
Jawed Zia is currently Head Pharmaceuticals, Novartis India. Zia succeeds Ranjit Shahani who holds this position until February 28, 2018.
Shares of Novartis India settled 1.04 per cent down at Rs 650.50 apiece on BSE today.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)